Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in western Kenya

Journal of Infectious Diseases

Volumn 187, Issue 3, 2003, Pages 467-476

  Terlouw, Dianne J ^a,b,c   Courval, Jeanne M ^a   Kolczak, Margarette S ^a   Rosenberg, Oren S ^a,b,e   Oloo, Aggrey J ^b,f   Kager, Piet A ^c   Lal, Altaf A ^a   Nahlen, Bernard L ^a,b,d   Ter Kuile, Feiko O ^a,b,c,g  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MOI UNIVERSITY   (Kenya)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; FALCIDIN; FANSIDAR; HALOFANTRINE; ORODAR;

AFRICA; AGE; ARTICLE; BODY WEIGHT; CARDIOTOXICITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INFANT; INTERNATIONAL STANDARD UNIT; KENYA; MAJOR CLINICAL STUDY; MALARIA; MALE; NEWBORN; PLASMODIUM FALCIPARUM; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TABLET; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

AGE FACTORS; ANIMALS; ANTIMALARIALS; BODY WEIGHT; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; INFANT; KENYA; MALARIA; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PYRIMETHAMINE; RETROSPECTIVE STUDIES; SULFADOXINE; TREATMENT FAILURE;

EID: 0037316971     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/367705     Document Type: Article

References (84)

1. Winstanley PA, Watkins WM, Newton CR, et al. The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. Br J Clin Pharmacol 1992; 33:143-8.
2. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 1993; 87:75-8.
3. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999; 353:1965-7.
4. Rieckmann K, Suebsaeng L, Rooney W. Response of Plasmodium falciparum infections to pyrimethamine-sulfadoxine in Thailand. Am J Trop Med Hyg 1987; 37:211-6.
5. Warsame M, Kilimali VA, Wernsdorfer WH, Lebbad M, Rutta AS, Ericsson O. Resistance to chloroquine and sulfadoxine-pyrimethamine in Plasmodium falciparum in Muheza district, Tanzania. Trans R Soc Trop Med Hyg 1999; 93:312-3.
6. Mutabingwa T, Nzila A, Mberu E, et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 2001; 358:1218-23.
7. Nzila AM, Nduati E, Mberu EK, et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis 2000; 181:2023-8.
8. Nwanyanwu OC, Ziba C, MacHeso A, Kazembe P. Efficacy of sulphadoxine-pyrimethamine for acute uncomplicated malaria due to Plasmodium falciparum in Malawian children under five years old. Trop Med Int Health 2000; 5:355-8.
9. Ekvall H, Premji Z, Bjorkman A. Micronutrient and iron supplementation and effective antimalarial treatment synergistically improve childhood anaemia. Trop Med Int Health 2000; 5:696-705.
10. White NJ. Why is it that antimalarial drug treatments do not always work? Ann Trop Med Parasitol 1998; 92:449-58.
11. World Health Organizaiton. Drug resistance in malaria. Report WHO/CDS/CSR/DRS/2001.4. Geneva: World Health Organization, 2001.
12. Bloland PB, Ruebush TK, McCormick JB, et al. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission I. Description of study site, general methodology, and study population. Am J Trop Med Hyg 1999; 60:635-40.
13. Bloland PB, Boriga DA, Ruebush TK, et al. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children. Am J Trop Med Hyg 1999; 60:641-8.
14. Aidoo M, Terlouw DJ, Kolczak MS, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002; 359:1311-2.
15. Beier JC, Oster CN, Onyango FK, et al. Plasmodium falciparum incidence relative to entomologic inoculation rates at a site proposed for testing malaria vaccines in western Kenya. Am J Trop Med Hyg 1994; 50:529-36.
16. McElroy PD, Beier JC, Oster CN, et al. Predicting outcome in malaria: correlation between rate of exposure to infected mosquitoes and level of Plasmodium falciparum parasitemia. Am J Trop Med Hyg 1994; 51:523-32.
17. Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, Campbell CC. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 1993; 167:932-7.
18. Terlouw DJ, Aidoo MA, Udhayakumar V, et al. Increased efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria among children with sickle cell trait in western Kenya. J Infect Dis 2002; 186:1661-8.
19. World Health Organization, Division of Control of Tropical Diseases. Severe and complicated malaria. Trans R Soc Trop Med Hyg 1990; 84(Suppl 2):1-65.
20. Kenya Ministry of Health. A simplified national guideline on malaria control for community resource persons. Nairobi, Kenya: Ministry of Health, 2000.
21. Zucker JR, Campbell CC. Malaria: principles of prevention and treatment. Infect Dis Clin North Am 1993; 7:547-67.
22. World Health Organization. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated malaria in areas with intense transmission. Report WHO/MAL/96.1077. Geneva: World Health Organization, 1996.
23. ter Kuile FO, Dolan G, Nosten F, et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 1993; 341:1044-9.
24. Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341:1113-4.
25. Dorsey G, Kamya MR, Ndeezi G, et al. Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg 2000; 62:686-92.
26. Fontanet AL, Walker AM. Predictors of treatment failure in multiple drug-resistant falciparum malaria: results from a 42-day follow-up of 224 patients in eastern Thailand. Am J Trop Med Hyg 1993; 49:465-72.
27. Hess FI, Iannuzzi A, Leafasia J, et al. Risk factors of chloroquine resistance in Plasmodium falciparum malaria. Acta Trop 1996; 61:293-306.
28. Hess FI, Nukuro E, Judson L, Rodgers J, Nothdurft HD, Rieckmann KH. Anti-malarial drug resistance, malnutrition and socio-economic status. Trop Med Int Health 1997; 2:721-8.
29. ter Kuile FO, Luxemburger C, Nosten F, Thwai KL, Chongsuphajaisiddhi T, White NJ. Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1995; 89:660-4.
30. Brandling-Bennett AD, Oloo AJ, Watkins WM, Boriga DA, Kariuki DM, Collins WE. Chloroquine treatment of falciparum malaria in an area of Kenya of intermediate chloroqulne resistance. Trans R Soc Trop Med Hyg 1988; 82:833-7.
31. ter Kuile FL, Terlouw DJ, Phillips-Howard PA, et al. Impact of permethrin-treated bednets on malaria and all-cause morbidity in young children in an area of intense perennial malaria transmission in western Kenya: cross-sectional survey. Am J Trop Med Hyg (in press).
32. World Health Organization. Chemotherapy of malaria and resistance to antimalarials. Technical report series no. 529. Geneva: World Health Organization, 1973.
33. Hardin J, Hilbe J. Generalized linear models and extensions. College Station, Texas: Stata Press, 2001.
34. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 1985; 122:904-14.
35. Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford textbook of medicine. 3rd ed. New York: Oxford University Press, 1996.
36. Behrman RE, Kliegman RM, Jenson HB, eds. Nelson textbook of pediatrics. 16th ed. Philadelphia: W. B. Saunders, 2000.
37. Mandell MD, Bennett JE, Dolin R. eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. Vol. 1. Philadelphia: Churchill Livingstone, 2000.
38. Elzouki AY, Harfi HA, Nazer HM, eds. Textbook of clinical pediatrics. Philadelphia: Lippincott, Williams, and Wilkins, 2001.
39. American Society of Health-System Pharmacists (ASHP). ASHP therapeutic guidelines for nonsurgical antimicrobial prophylaxis. Am J Health Syst Pharm 1999; 56:1201-50.
40. Mehlhorn H, ed. Encyclopedic reference of parasitology. 2nd ed. Berlin: Springer, 2001.
41. US NaW Medical Department. Navy, medical department pocket guide to malaria prevention and control. Norfolk, VA: US Navy, Medical Department, 2000.
42. Marx JA, Hockberger RS, Walls RM, eds. Rosen's emergency medicine: concepts and clinical practice. 5th ed. St. Louis: Mosby, 2002.
43. Beers MH, Berkow R, eds. The Merck manual of diagnosis and therapy. 17th ed. New York: Merck Research Laboratories, 1999.
44. Hay WW, Hayward AR, Levin MJ, Sondheimer JM, eds. Current pediatric diagnosis and treatment. 14th ed. Stamford, CT: Appleton & Lange, 1999.
45. Rudolph AM, Hoffman JIE, Rudolph CD, eds. Rudolph's pediatrics. 20th ed. Stamford, CT: Appleton & Lange, 1996.
46. Burg FD, Ingelfinger JR, Wald ER, eds. Gellis and Kagan's current pediatric therapy. 14th ed. Philadelphia: W. B. Saunders, 1993.
47. Moses S. Family practice notebook, 2000. Available at http://www.fpnotebook.com.
48. Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. 21st ed. Boston: Blackwell Science Publications, 2001.
49. Pickering LK, ed. American Academy of Pediatrics 2000 red book: report of the committee on infectious diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000.
50. Strickland GT, ed. Hunter's tropical medicine. 8th ed. Philadelphia: W. B. Saunders, 2000.
51. Malawi Ministry of Health and Population. Malawi guidelines for the management of malaria for medical officers, clinical officers, medical assistants and nursing staff. Lilongwe, Malawi: Ministry of Health, 1997.
52. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. 42nd ed. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2001.
53. Fansidar South African electronic package insert. Roche Pharmaceuticals, 2001. Available at http://home.intekom.com/pharm/roche/fansidat.html.
54. Physicians' desk reference. 53rd ed. Montvale, NJ: Medical Economics, 1999.
55. Malawi malaria control committee. Guide for management of acute falciparum malaria in Malawi for physicians, clinical officers, medical assistants and senior nursing staff. Lilongwe, Malawi: Ministry of Health, 1986.
56. Mosby's drug consult. St. Louis: Mosby, 2002. Available at http://home.mdconsult.com.
57. Kenya Ministry of Health. Kenya national policy document for malaria control. Nairobi, Kenya: Ministry of Health, 1997.
58. Kenya Ministry of Health. National Guidelines for Diagnosis, treatment, and prevention of malaria for health workers. Nairobi, Kenya: Ministry of Health, 1998.
59. World Health Organization. International travel and health. Geneva: World Health Organization, 1998.
60. World Health Organization. Management of uncomplicated malaria and the use of antimalarials drugs for the protection of travellers. Report WHO/MAL/96.1075Rev.1. Geneva: World Health Organization, 1995.
61. Laboratory Center for Disease Control Health Canada. 2000 Canadian recommendations for the prevention and treatment of malaria among international travellers. Laboratory Center for Disease Control Health Canada, 2000. Available at http://www.hc-sc.gc.ca/hpb/lcdc.
62. World Health Organization. The use of antimalarial drugs. Report WHO/CDS/RBM/2001.33. Geneva: World Health Organization, 2000.
63. Ministry of Health Tanzania. National guidelines for malaria diagnosis and control. Dares Salaam, Tanzania: Ministry of Health, 2000.
64. World Health Organization. International travel and health. Geneva: World Health Organization, 1995.
65. Rakel RR, Bope ET, eds. Conn's current therapy 2001. 53rd ed. Philadelphia: W. B. Saunders, 2001.
66. Cook GC, ed. Manson's tropical diseases. London: W. B. Saunders, 1996.
67. Eddleston M, Pierini S, eds. Oxford handbook of tropical medicine. Oxford: Oxford University Press, 1999.
68. Gillespie SH, Pearson RD, eds. Principles and practice of clinical parasitology. Chichester, UK: John Wiley & Sons, 2001.
69. UNICEF's programme division. The prescriber: promoting rational use of drugs and correct case management in basic health services, malaria prevention and treatment. Geneva: United Nations Children's Fund, 2000.
70. Govere JM, la Grange JJ, Durrheim DN, et al. Sulfadoxine-pyrimethamine effectiveness against Plasmodium falciparum malaria in Mpumalanga Province, South Africa. Trans R Soc Trop Med Hyg 1999; 93:644.
71. Kenya Ministry of Health. Clinical guidelines for diagnosis and treatment of common hospital conditions in Kenya. Nairobi, Kenya: Ministry of Health, 1994.
72. Fansidar electronic package insert. Roche Pharmaceuticals, 1996. Available at http://www.rocheusa.com/products/fansidar/pi.html.
73. Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother 2000; 44:3414-24.
74. Kun JF, Lehman LG, Lell B, Schmidt-Ott R, Kremsner PG. Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drug-resistant Plasmodium falciparum strains. Antimicrob Agents Chemother 1999; 43:2205-8.
75. Price R, Nosten F, Simpson JA, et al. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg 1999; 60:1019-23.
76. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347:1654-8.
77. Robert V, Molez JF, Trape JF. Short report: gametocytes, chloroquine pressure, and the relative parasite survival advantage of resistant strains of falciparum malaria in west Africa. Am J Trop Med Hyg 1996; 55:350-1.
78. von Seidlein L, Drakeley C, Greenwood B, Walraven G, Targett G. Risk factors for gametocyte carriage in Gambian children. Am J Trop Med Hyg 2001; 65:523-7.
79. Targett G, Drakeley C, Jawara M, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis 2001; 183:1254-9.
80. Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R, Campbell CC. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35:451-8.
81. Hernborg A. Stevens-Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique. Lancet 1985; 2:1072-3.
82. Sturchler D MM, Kerr L. How frequent are notified severe cutaneous adverse reactions to Fansidar? Drug Safety 1993; 8:160-8.
83. Bergoend H, Loffler A, Amar R, Maleville J. Cutaneous reactions appearing during the mass prophylaxis of cerebrospinal meningitis with a long-delayed action sulfonamide (apropos of 997 cases) [in French]. Ann Dermatol Syphiligr (Paris). 1968; 95:481-90.
84. Nakazawa S, Kanbara H, Aikawa M. Plasmodium falciparum: recrudescence of parasites in culture. Exp Parasitol 1995; 81:556-63.